Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).

Trial Profile

Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Motolimod (Primary) ; Cetuximab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Jan 2014 According to ClinicalTrials.gov record, planned End Date changed from 1 Dec 2013 to 1 Dec 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top